Published in final edited form as:

Exp Cell Res. 2016 July 15; 345(2): 255. doi:10.1016/j.yexcr.2016.05.021.

Erratum to “Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF- β pathways in MCF-7 cancer cells with PX-866 and Raloxifene” [*Exp. Cell Res.* 344 (2016) 95-102].

GW Peek¹, TO Tollefsbol²

¹Department of Biology, University of Alabama at Birmingham, Birmingham, AL, USA.

²Department of Biology, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Center for Healthy Aging, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL, USA; Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.

The publisher regrets that [Table 1](#) was published incorrectly. The correct table appears below.

The publisher would like to apologise for any inconvenience caused.

Table 1.

Significant relative levels of mRNA, protein and phosphorylated protein following three days of treatment with Raloxifene and/or PX-866.

Micromolar treatment	<i>TERT</i>	<i>p21</i>	<i>Cyc D1</i>	<i>Axin2</i>	<i>LIF</i>	<i>HB EGF</i>	<i>DEC1</i>
Control	1.00	1.00	1.00	1.00	1.00	1.00	1.00
1.0 Raloxifene				0.328*	0.158*	0.338*	
0.4 PX-866							
Raloxifene+0.1 PX-866	0.396*		0.398*	0.260*	0.283*	0.370*	
Raloxifene+0.4 PX-866	0.539*		0.336*				
Raloxifene+0.8 PX-866		2.76*	0.356*				1.95*
Micromolar treatment	pMDM2 protein						
Control	1.0						
1.0 Raloxifene							
0.4 PX-866	0.379*						
Raloxifene +0.1 PX-866	0.395*						
Raloxifene +0.4 PX-866	0.385*						
Raloxifene +0.8 PX-866	0.353*						

*
p<0.05.